Skip to main content
. 2022 Sep 5;10(9):2194. doi: 10.3390/biomedicines10092194

Figure 2.

Figure 2

Figure 2

All-cause mortality in different dosing regimens in moderate and severe disease cohorts [19,21,22,23,24,25,50,52,53,54,55,56]. (A) All-cause mortality in severe and moderate disease cohorts; (B) all-cause mortality in cohorts where intermediate or therapeutic dose was used in the HD group.